Novo Nordisk A/S

14 registered trials on this site, 2 active. This page lists the trials this organization is registered as lead sponsor of, for the compounds covered on PeptideBlog.net. It is a registry listing, not an assessment of the company or its products.

Compounds covered

Registered trials

Trial	Compound	Phase	Status	Sponsor	Enrolled	Primary completion	Registry updated
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight NCT05567796	Cagrilintide	Phase 3	Active not recruiting	Novo Nordisk A/S	3,400	Oct 30, 2024	Sep 30, 2026
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo NCT06131372	Cagrilintide	Phase 2	Completed	Novo Nordisk A/S	626	Sep 24, 2025	Sep 24, 2026
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism NCT07010432	Cagrilintide	Phase 1	Recruiting	Novo Nordisk A/S	144	May 3, 2028	Sep 10, 2026
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet NCT07184086	Cagrilintide	Phase 1	Active not recruiting	Novo Nordisk A/S	80	Oct 12, 2027	Sep 10, 2026
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin NCT06323161	Cagrilintide	Phase 3	Completed	Novo Nordisk A/S	274	Sep 9, 2025	Sep 9, 2026
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide NCT07220759	Cagrilintide	Phase 3	Active not recruiting	Novo Nordisk A/S	330	May 12, 2027	Sep 4, 2026
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide NCT07220642	Cagrilintide	Phase 3	Active not recruiting	Novo Nordisk A/S	300	May 11, 2027	Aug 6, 2026
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor NCT06065540	Cagrilintide	Phase 3	Completed	Novo Nordisk A/S	2,734	Nov 19, 2025	Jul 8, 2026
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events NCT07607587	Cagrilintide	Phase 1	Recruiting	Novo Nordisk A/S	114	Nov 19, 2027	Jun 25, 2026
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight NCT06131437	Cagrilintide	Phase 3	Completed	Novo Nordisk A/S	809	Dec 8, 2025	Feb 6, 2026
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes NCT04982575	Cagrilintide	Phase 2	Completed	Novo Nordisk A/S	92	Jul 7, 2022	Dec 23, 2025
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) NCT05016882	Cagrilintide	Phase 2	Completed	Novo Nordisk A/S	698	Dec 17, 2024	Nov 19, 2025
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. NCT03856047	Cagrilintide	Phase 2	Completed	Novo Nordisk A/S	706	Mar 2, 2020	Jul 5, 2024
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese NCT03600480	Cagri-Sema, Cagrilintide	Phase 1	Completed	Novo Nordisk A/S	96	Jun 12, 2020	Nov 17, 2021

Data: ClinicalTrials.gov, U.S. National Library of Medicine. See the full trial tracker.

Novo Nordisk A/S

Novo Nordisk A/S

Compounds covered

Registered trials

Explore

Beginner guides

Research areas

Tools and pipeline